ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1463

Anti-Cyclic Citrullinated Peptide Antibody Subclass Phenotypes in Polyarticular Juvenile Idiopathic Arthritis

Hannah Peckham1, Lauren Bourke2,3, Anna Radziszewska4, Maria Leandro5, Debajit Sen2, Geraldine Cambridge6 and Yiannis Ioannou7,8, 1Adolescent Centre for Rheumatology Research, University College London, London, United Kingdom, 2Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, 3Centre for Rheumatology Research, University College London, London, United Kingdom, 4The Rayne Institute, Arthritis Research UK Centre for Adolescent Rheumatology at University College London, Great Ormond Street Hospital and UCLH, University College London, London, United Kingdom, 5Centre for Rheumatology, University College London, London, United Kingdom, 6Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, 7Arthritis Research UK Centre for Adolescent Rheumatology at University College London, Great Ormond Street Hospital and UCLH, University College London, London, United Kingdom, 8Centre for Rheumatology Research, University College Hospital London, London, United Kingdom

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: autoantibodies, juvenile idiopathic arthritis (JIA), rheumatic disease and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2015

Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects Posters. Juvenile Arthritis and Miscellaneous Rheumatic Diseases

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Raised levels of Rheumatoid Factor (RhF) and antibodies to citrullinated proteins (ACPA), detected in the clinic using combinations of cyclic citrullinated peptides (CCP), are persistently demonstrated in adult Rheumatoid Arthritis (RA) serology. Multiple isotypes of both autoantibodies can be detected months or years prior to the onset of clinical manifestations. IgG-ACPAs are generally accepted as having greater diagnostic specificity than IgM-RhF, which are present in ~10% of the healthy population. IgG-ACPAs have also been detected in sera of patients with Juvenile Idiopathic Arthritis (JIA); in particular those with IgM-RhF+ve polyarticular JIA (poly-JIA), a subset often considered comparable to adult RA. The prevalence and predictive value of ACPA of IgG, IgM and IgA isotype has been extensively studied in adults with RA, but not, to our knowledge, in a juvenile population. This study profiles a large adolescent JIA cohort using CCP as substrate, with the aim to establish a distinct ACPA phenotype for RhF+ve poly-JIA patients, when compared to other JIA subtypes.

Methods:

Levels of anti-CCP antibodies from a total of 95 patients with poly-JIA (RhF–ve; n=67 and RhF+ve; n=24) were compared with age-matched disease controls (Enthesitis-Related Arthritis (ERA) n=29; Extended-Oligoarthritis (EOA) n= 38) and 31 age-matched healthy controls (HCs). Sera were tested for IgG, IgA and IgM isotypes of anti-CCP, using commercial ELISA plates, coated with second generation citrullinated peptides (CCP2). Cut-offs for positivity were defined by manufacturer’s instructions for IgG-CCP (5U/ml). The median age of the poly-JIA patients was 17.4 yrs (IQ range 15.9 to 19.0), with a median disease duration of 8.6 years. RhF status of the poly-JIA cohort was determined from the clinical records. Statistical analysis determined by Mann-Whitney U test.

Results:

In the poly-JIA cohort 87.5% (21/24) of IgM-RhF +ve patients were IgG-CCP+ve, compared with only 6.0% (4/67) of IgM-RhF-ve patients. Furthermore, when compared to control groups, only 2.6% of EOA patients (1/38) and none of the ERA (0/29) or HCs (0/31) were IgG-CCP positive. When results for IgM-RhF+ve/IgG-CCP+ve (n=21) poly-JIA patients were compared with those of the seronegative poly- JIA cohort (IgM-RhF -ve/IgG-CCP–ve; n=67) levels of IgA-CCP (6.47 (IQ range 4.43-15.74)  vs 2.95 (IQ range 2.48-4.37);p<0.0001) and IgM-CCP (69.03 (IQ range 38.03-180.5)  vs 40.52 (IQ range 27.0-66.88);p=0.0223) were significantly higher in the seropositive (IgM-RhF+ve/IgG-CCP+ve) group.

Conclusion:

This is the first study to our knowledge that profiles autoantibodies against CCP in a large adolescent JIA patient cohort. Results suggested a significantly higher proportion of poly-JIA patients who are IgM-RhF +ve being IgG-CCP positive when compared to those who were IgM-RhF–ve.  Additionally, patients who are IgM-RhF+ve/IgG-CCP+ve had significantly higher levels of both IgA-CCP and IgM-CCP antibodies when compared to patients who were IgM-RhF–ve/IgG-CCP–ve.  This data suggests that the serological profile of IgM-RF +ve poly-JIA patients mirrors that described in seropositive adult patients with RA.


Disclosure: H. Peckham, None; L. Bourke, None; A. Radziszewska, None; M. Leandro, None; D. Sen, None; G. Cambridge, None; Y. Ioannou, None.

To cite this abstract in AMA style:

Peckham H, Bourke L, Radziszewska A, Leandro M, Sen D, Cambridge G, Ioannou Y. Anti-Cyclic Citrullinated Peptide Antibody Subclass Phenotypes in Polyarticular Juvenile Idiopathic Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/anti-cyclic-citrullinated-peptide-antibody-subclass-phenotypes-in-polyarticular-juvenile-idiopathic-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-cyclic-citrullinated-peptide-antibody-subclass-phenotypes-in-polyarticular-juvenile-idiopathic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology